Dexcom G7 Study Shows Significant A1C Reduction in Type 2 Diabetes Patients

Key Facts

In a strategic move to broaden the application of glucose monitoring technology, DexCom released results from its CONNECT clinical trial. The study demonstrated that the Dexcom G7 continuous glucose monitoring (CGM) system significantly lowers A1C levels in Type 2 diabetes patients who do not use insulin. According to reports, the G7 system outperformed traditional blood glucose fingersticks in improving glycemic control, marking a potential shift in the standard of care for this patient demographic.

The clinical data aims to establish CGM devices as a primary care tool for a wider user base, potentially expanding DexCom's total addressable market beyond insulin-dependent patients. Per market data and analyst assessments, while these positive clinical results support long-term market expansion into the non-insulin Type 2 segment, the immediate impact on revenue is expected to be gradual.

Regarding market performance, DXCM closed at $90.22 as of August 20, 2026, having traded between a high of $91.39 and a low of $89.28 during that session. Investors monitoring the healthcare sector may also look toward broader US economic indicators, such as upcoming Building Permits and Housing Starts data, for signals on consumer spending capacity and its indirect influence on medical technology adoption.